ASCO Guidelines
Avsnitt

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline 2026.1.0

ASCO Guidelines
Dela

Drs. Jamie Lesnock and Sara Bouberhan join the podcast to discuss the first ASCO guideline on systemic treatment for recurrent ovarian cancer. They provide a comprehensive overview of the evidence-based recommendations for patients with both platinum-sensitive and platinum-resistant or platinum-refractory disease. The discussion covers systemic therapy options, the role of maintenance therapy with agents like bevacizumab, and the nuanced recommendations for secondary cytoreductive surgery based on mixed clinical trial results. Drs. Lesnock and Bouberhan emphasize the importance of an individualized, multidisciplinary approach to care. As this is a living guideline, they also look ahead to emerging evidence that will shape future updates.

Read the full living guideline, "Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0," at www.ascopubs.org/guidelines/systemic-treatment-ovarian-cancer-recurrence"

LINK TO FULL TRANSCRIPT

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör American Society of Clinical Oncology (ASCO). Innehållet i podden är skapat av American Society of Clinical Oncology (ASCO) och inte av, eller tillsammans med, Poddtoppen.